MABTAS RA 500MG
                     MABTAS RA 500MG
DESCRIPTION
 Mabtas RA 500mg  is an anticancer medicine which prevents the growth and spread of
cancer cells in the body.  Mabtas RA 500mg injection  also indicated for the treatment 
of Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with 
another anticancer drugs like methotrexate is used for rheumatoid arthritis symptoms 
in adult treatment.  Mabtas RA 500mg  with steroid regimen combination is given for 
the treatment of some rare disorders which cause blood vessels and other tissues 
inflammation in the body.
INDICATION
Mabtas RA 500mg and hyaluronidase human injection are given alone or combination
with other drugs to treat certain types of non-Hodgkin's lymphoma and chronic 
lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg injection is also used with methotrexate (Otrexup, Rasuvo, 
Xatmep, others) for the treatment rheumatoid arthritis symptoms in adults that have 
been already treated with some type of regimenknown as tumor necrosis factor (TNF) 
inhibitor.
Mabtas RA 500mg is a type in a classification of drugs called monoclonal antibodies. 
Mabtas RA 500mg injection is used to killing cancer cells to treat NHL,CLL, 
rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis 
by stopping the activity of the part of the immune system that will damage the joints, 
veins, and other blood vessels and cause damage to organs (heart and lungs).
MECHANISM OF ACTION
 Mabtas RA 500mg  is a type of class called as monoclonal antibody and which is a 
new type of "targeted" cancer treatment and an integral part of the body's immune 
system. Naturally the body build antibodies in along with to an antigen which has 
entered the body and attach to the antigen for destruction by the immune system.
An essential cells only aimed by monoclonal antibiotics, they may leads to less 
toxicity to healthy cell and it is usually treatment recommended only for cancers in 
which antigens (and the respective antibodies) have been already identified.
Mabtas RA 500mg injection works by linking to the CD20 antigen on normal and 
malignant B-cells. Hence the body's essential immune security is initiated to attack 
and kill the marked B-cells. Stem cells i.eyoung cells in the bone marrow which will 
grow into the various cell types and do not have the CD20 antigen. After treatment, 
CD20 antigen allows healthy B-cells to multiply
PRODUCT DETAILS
Brand : Mabtas RA
Ingredients : Rituximab
Strength : 500mg
Manufactured : Intas pharmaceuticals ltd
Package : injection
Mabtas ra 500mg
PHARMACOKINETICS
ABSORPTION
Not available
DISTRIBUTION
volume of distribution is 3.1 L
METABOLISM
Mabtas RA 500mg metabolized by human antimurine antibody production.
EXCRETION
not available
The half-life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic 
polyangiitis is 23 days
DOSAGE MANAGEMENT
Mabtas RA 500mg injection is recommended to administer only through intravenous 
infusion not by IV push or bolus.
BEFORE EACH INFUSION PREMEDICATE 
First infusion: initially rate of 50 mg/hr. is given, in not showing infusion toxicity, rate
raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
Successive infusion: 100 mg/hr.-initiatedrate, in not showing infusion toxicity, rate 
raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
Premedication with corticosteroids must be considered, if Mabtas RA 
500mg combination with CHOP chemotherapy is not given.
LOW GRADE OR FOLLICULAR NON-HODGKINS LYMPHOMA
Dose is 375 mg/m2 as an IV infusion.
Once weeksfor 4 or 8 doses administrated for Relapsed treatment
Relapsed Retreatment for once weekly for 4 doses administrated.
Untreated Previously: given on day 1 of each cycle of chemotherapy, up to 8 doses. In
complete or partial response of patient, start with 8 weeks for maintenance following 
Mabtas RA in combination with chemotherapy completed then administer 8weeks for 
12 doses as a single agent.
Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – 
progression (following CVP chemotherapy completion 6 – 8 cycles)
On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse large B- cell NHL.
CHRONIC LYMPHOCYTIC LEUKEMIA 
Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 
mg/m2 on day 1 of 2-6 cycles every 28 days.
COMPONENT OF ZEVALIN FOR TREATMENT OF NHL
Prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) 
Zevalin administer Mabtas RA infusion about 250 mg/m2 within 4 hours
Before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin 7–9 
days.
RHEUMATOID ARTHRITIS 
 Mabtas RA 500mg  is administer with methotrexate combination
Mabtas RA 500mg injection administrating as two doses of 100mg IV infusion 2 
weeks separated.
When glucocorticoids administered as methyl prednisolone 100mg IV
Subsequent course based on clinical evaluation should administer every 24 weeks, but
not early than every 16 weeks.
GRANULOMATOSIS POLYANGITIS AND MICROSCOPIC POLYANGITIS 
Weekly once for 4 weeks administer Dose of 375 mg/m2 IV infusion
While Glucocorticoids combination with methylprednisolone by dose of 1000 mg IV/ 
day given for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended 
for the treatment of symptoms of seriousvasculitis . This drug should initiate within 14
days before or with the starting of Mabtas RA and may continue during and after the 
4-week course with treatment of  Mabtas RA 500mg  drug.
Safety and not established for subsequent infusion.
ADMINISTRTION
Take an  Mabtas RA 500mg injection  amount and diluted to final concentration of 1 
mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in 
water). Invert gently the bag and mix the solution. Dispose unused drug left in vial.
Chronic lymphocytic leukemia
PRECAUTIONS
Allergic condition against Mabtas RA 500mg or any other medication informs your 
doctor.
Concerning your history of drug used which include in prescription, non-prescription, 
vitamins &supplements, nutritional products just inform the doctor.
While using Mabtas RA 500mg injection do not take any vaccination or immunization
without taking advice from doctors.
Avoid use of Mabtas RA 500mg if you are pregnant. It will harm the baby unborn, 
while using  Mabtas RA 500mg injection  use correct birth control to prevent 
pregnancy and for at least 2 weeks after your treatment ends.  Mabtas RA 500mg  may 
affect the ability to have children in women. Inform your doctor if you planning to 
pregnant.
It is unknown whether  Mabtas RA 500mg injection  passes into breast milk, avoid 
breast-feed while on Mabtas RA 500mg treatment.
SIDE EFFECTS
Common effects:
fever and chills (flu like symptoms)
Less common side effects:
Weakness; nausea; headache; cough; dyspnea; pharyngitis
DRUG INTERACTION
Mabtas RA 500mg injection drug interaction has limited data is available at present.
Combination with fludarabine or cyclophosphamide has no effects in 
pharmacokinetics in CLL patients.
Combination with methotrexate had no effects in pharmacokinetics.
CONTRAINDICATIONS
Hypersensitivity or murine proteins.
Active severe infections in rheumatoid arthritis
Uncontrolled cardiac disease.
PREGNANCY
Category C: animal studies reproduction shown an adverse effect on the fetus. The 
drug has no enoughand well controlled studies in humans, using in pregnant women 
benefits by warrant use of the drug.
LACTATION
 Mabtas RA 500mg  excreted into human milk is unknown. Due to the drug belongs to 
large protein molecule, no information is available. Women should not breast feed 
during Mabtas RA 500mg treatment and 12 months following last dose.
STORAGE 
• Store at 20°C – 30°C
• Use the drug before expiry date
• Protected from direct sunlight
• Do not freeze or shake.
• Keep away from the children’s
• Discard the unused drug by asking the advice from doctor or pharmacist.
MISSED DOSE
Mabtas RA 500mg injection excreted into human milk is unknown. Due to the drug 
belongs to large protein molecule, no information is available. Women should not 
breast feed during Mabtas RA 500mg treatment and 12 months following last dose.
OVERDOSAGE
If the patients had high dose of  Mabtas RA 500mg  then seek immediately to the 
emergency department or poison control help line. Please consult the doctor for 
further clarification.
CONTACT US 
PHONE NO : +91-9940472902
EMAIL : [email protected]
WEBSITE URL : https://millionpharma.com/mabtas-ra-500mg.php
.